Our Pipeline

We own worldwide development and commercialization rights to each of our product candidates.

Pathway Program Indication Preclinical IND-Enabling Phase I Phase II Phase III
LANCL2BT-11Ulcerative Colitis
Crohn's Disease
Eosinophilic Esophagitis
Psoriasis
BT-104Lupus
Rheumatoid Arthritis
BT-111NASH
Type 1 Diabetes
NLRX1NX-13Ulcerative Colitis
Crohn's Disease
NX-66Multiple Sclerosis
Alzheimer's Disease
NX-73Asthma
COPD
PLXDC2PX-69Diabetic Nephropathy
Rheumatoid Arthritis

BT-11 has the Potential to Exert Anti-Inflammatory Effects within the Gastrointestinal Track

BT-11, our lead product candidate, is a first-in-class, gut-restricted oral therapeutic candidate that targets LANCL2, a membrane receptor that has been shown to modulate immunological mechanisms that are associated with the autoimmune diseases: ulcerative colitis (UC) and Crohn’s disease (CD).  Based on clinical data to date, BT-11 may address the main limitations of current therapies with a convenient once a day dosing that offers low systemic exposure, improved tolerability and no ties to toxicities.

Landos is currently conducting a Phase 2 trial of BT-11 in patients affected by mild to moderate UC in the U.S. EU and Russia and expects to report topline data in the second half of 2020.

Landos expects to conduct a Phase 2 trial in patients affected by moderate to severe CD in the first half of 2021.

BT-11 Diagram

Reprogramming Immune Responses in Autoimmune Diseases

NX-13 also has the Potential to Exert Anti-Inflammatory Effects within the Gastrointestinal Tract

NX-13 is a first-in-class novel, gut-restricted oral therapeutic candidate that targets NLRX1 (NOD-like receptor X1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. In preclinical comparative efficacy studies to 5-ASA and anti-TNF-alpha therapeutics, NX-13 demonstrated significantly greater changes in disease activity, biomarkers and histological parameters.

Landos is completing a Phase 1 trial of NX-13 for the treatment of UC and CD in 2020, and expects to report topline data in the second half of 2020.